Industry & Business

EpiCor Therapeutics wins UCD Start-up of the Year Award

 Breaking News
  • Arkphire Secures New Investment IT solutions and networking company, Arkphire, has announced that Bregal Milestone, a private capital firm, has completed an investment into the business. The investment by Bregal Milestone comes from their new €400 million pan-European fund dedicated to investing in high-growth European companies. Typical commitments from Bregal Milestone range from €20 million to €60 million. Arkphire provides [...]...
  • Government Investment in Research & Development Amounts to Over €750 Million in 2018 The latest figures on Government investment in research and development (R&D), published by the Department of Business, Enterprise and Innovation, show that over €750 million is estimated to have been invested in R&D in 2018. The data in The Research and Development Budget 2017-2018 publication is compiled from a comprehensive survey of thirty Government Departments [...]...
  • Smart Dublin in Partnership With Enterprise Ireland Award 21 New Innovation Contracts Approximately €700,000 is to be awarded to companies under Enterprise Ireland’s Small Business Innovation Research (SBIR) initiative which will enable them explore innovative solutions to address challenges faced by Local Authorities. 21 companies have been awarded Phase One funding to progress the feasibility of their solutions. Phase One funding will allow each recipient to carry [...]...
  • Tourism Industry Barometer Reflects Buoyant Year But Hints at Brexit Concerns Tourism performance throughout 2018 continues to be on a strong footing, according to the latest Fáilte Ireland Tourism Barometer. The survey of more than 500 tourism businesses around the country shows over half of the tourism industry is reporting their business to be up, with two thirds (64%) saying that tourism agency supports have been [...]...
  • Glanbia to Acquire SlimFast For $350 Million Glanbia, the global nutrition group, has agreed to acquire SlimFast and other brands for $350 million from the owners KSF Holdings LLP and HNS Intermediate Corporation. SlimFast is a leading weight management and health & wellness brand family distributed primarily in the food, drug, mass and club (FDMC) channel in the US and UK. It [...]...

EpiCor Therapeutics wins UCD Start-up of the Year Award

EpiCor Therapeutics wins UCD Start-up of the Year Award
November 23
13:18 2016

Biotech start-up EpiCor Therapeutics won the UCD Start-Up of the Year Award 2016 on Thursday, November 17. It received a €20,000 prize as part of the overall winner award of the UCD VentureLaunch Accelerator Programme. The start-up is aiming to develop a treatment for hypertrophic obstructive cardiomyopathy (HOCM), a significant cause of sudden cardiac death.

HOCM is a disease in which a portion of the heart muscle is enlarged without any obvious cause resulting in impairment of the heart. Symptoms include shortness of breath, chest pain and heart palpitations. In the US alone, HOCM currently affects around 175,000 people with associated annual healthcare costs amounting to over $1 billion.

EpiCor Therapeutics is currently focused on repurposing an existing drug, 5-azacytidine, for the treatment of HOCM. It will also investigate the use of biomarkers to deliver targeted treatment for individuals.

EpiCor Therapeutics was founded by Dr John Baugh, Dr Nadia Glezeva, Dr Chris Watson, Dr Mark Ledwidge and Professor Ken McDonald, all of UCD School of Medicine.

“It is an honour for EpiCor Therapeutics to win the 2016 UCD Start-up of the Year Award,” said Dr John Baugh. “It is a great endorsement for us going forward as we work to develop treatments to target a variety of heart diseases, including our initial focus on hypertrophic obstructive cardiomyopathy.

The disease has no approved disease-modifying therapeutics, is a significant cause of sudden cardiac death of individuals in any age group and a leading cause of such death in young athletes.

EpiCor Therapeutics is now seeking to raise €750,000 in seed funding to enable pre-clinical bridging studies. Following additional fund raising, it plans to proceed with a clinical proof-of-concept study to support its approval as a treatment for HOCM.

UCD’s annual VentureLaunch Accelerator Programme aims to support and accelerate the launch of sustainable and profitable new ventures based on intellectual property emerging from the university.

About Author

editor

editor

Related Articles

New Subscriber





Subscribe Here



Advertisements



















National Manufacturing Conference & Exhibition 2018

NIBRT Springboard Success Stories



Upcoming Events

  • No upcoming events
AEC v1.0.4